We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

We recently compiled a list of the 13 Cheap High Dividend Stocks To Invest In Now. In this article, we are going to take a ...

Other companies with 20 or more are AbbVie, Amgen, AstraZeneca, GSK, Merck, Roche and Sanofi. Related Amid Biden admin's drug-pricing push, Big Pharma kicks off 2024 with hundreds of price hikes ...

This year has seen the US FDA approve 45 new chemical or biologic new entities, exceeding last year's tally of 40, and showing a continued resurgence in the pharma sector's R&D productivity.

Merck & Co’s CEO Kenneth Frazier ... September that showed the reputation of the pharma industry was at rock bottom, below all others on the list. Among those questioned 58% had a “totally ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other ...